Absci to Participate in the 31st Annual Credit Suisse Healthcare Conference

Rhea-AI Summary

Absci Corporation (Nasdaq: ABSI) announced participation in the Credit Suisse Annual Healthcare Conference to be held in Rancho Palos Verdes, CA, on November 10, at 9:10 a.m. PT. The event will feature a fireside chat with Absci management, which can be accessed via a live and archived webcast on their investor relations website. Absci focuses on protein drug creation, utilizing generative AI and biological data to advance therapeutic development.

VANCOUVER, Wash. and NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), leaders in the protein drug creation revolution harnessing generative AI and scalable biological data to design better therapeutics, faster, today announced the company will be participating in the upcoming Credit Suisse Annual Healthcare Conference in Rancho Palos Verdes, CA.

Absci management is scheduled to participate in a fireside chat on Thursday, November 10^th at 9:10 a.m. Pacific Time (12:10 p.m. Eastern Time). Interested parties may access a live and archived webcast of the presentation on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic™ proteins containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com and follow us on social media: Twitter: @Abscibio, LinkedIn: @absci, and subscribe to our Absci YouTube channel.

Availability of Other Information about Absci

Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on Twitter, LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact
investors@absci.com

Media Contact
press@absci.com

FAQ

What is Absci Corporation's participation in the Credit Suisse Annual Healthcare Conference?

Absci Corporation will participate in the Credit Suisse Annual Healthcare Conference on November 10, 2022, featuring a fireside chat at 9:10 a.m. PT.

How can I access the webcast of Absci's presentation at the Credit Suisse conference?

The webcast of Absci's presentation can be accessed live and archived on their investor relations website at investors.absci.com.

When is Absci's fireside chat scheduled during the Credit Suisse Annual Healthcare Conference?

The fireside chat featuring Absci's management is scheduled for November 10, 2022, at 9:10 a.m. Pacific Time.

What focus does Absci Corporation have in the biotech industry?

Absci is focused on utilizing deep learning AI and synthetic biology for drug discovery and target identification, aiming to develop innovative protein-based therapeutics.

What technologies does Absci utilize in creating therapeutic proteins?

Absci employs generative AI and scalable biological data within its Integrated Drug Creation™ platform to enhance the development of therapeutic proteins.